Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Fate Therapeutics (FATE) EBIT (2016 - 2025)

Historic EBIT for Fate Therapeutics (FATE) over the last 14 years, with Q3 2025 value amounting to -$34.7 million.

  • Fate Therapeutics' EBIT rose 3368.27% to -$34.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$174.7 million, marking a year-over-year increase of 1112.5%. This contributed to the annual value of -$210.3 million for FY2024, which is 1037.47% down from last year.
  • According to the latest figures from Q3 2025, Fate Therapeutics' EBIT is -$34.7 million, which was up 3368.27% from -$37.0 million recorded in Q2 2025.
  • In the past 5 years, Fate Therapeutics' EBIT ranged from a high of -$28.6 million in Q1 2023 and a low of -$86.4 million during Q3 2022
  • In the last 5 years, Fate Therapeutics' EBIT had a median value of -$51.3 million in 2023 and averaged -$54.7 million.
  • As far as peak fluctuations go, Fate Therapeutics' EBIT tumbled by 10773.68% in 2021, and later surged by 6160.45% in 2023.
  • Quarter analysis of 5 years shows Fate Therapeutics' EBIT stood at -$69.4 million in 2021, then grew by 7.15% to -$64.4 million in 2022, then grew by 25.37% to -$48.1 million in 2023, then dropped by 28.44% to -$61.7 million in 2024, then skyrocketed by 43.75% to -$34.7 million in 2025.
  • Its EBIT stands at -$34.7 million for Q3 2025, versus -$37.0 million for Q2 2025 and -$41.3 million for Q1 2025.